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Abstract The nephron is the functional unit of the kidney.
Blood and plasma are continually filtered within the
glomeruli that begin each nephron. Adenosine 5′ triphos-
phate (ATP) and its metabolites are freely filtered by each
glomerulus and enter the lumen of each nephron beginning
at the proximal convoluted tubule (PCT). Flow rate,
osmolality, and other mechanical or chemical stimuli for
ATP secretion are present in each nephron segment. These
ATP-release stimuli are also different in each nephron
segment due to water or salt permeability or impermeability
along different luminal membranes of the cells that line
each nephron segment. Each of the above stimuli can trigger
additional ATP release into the lumen of a nephron segment.
Each nephron-lining epithelial cell is a potential source of
secreted ATP. Together with filtered ATP and its metabolites
derived from the glomerulus, secreted ATP and adenosine
derived from cells along the nephron are likely the principal
two of several nucleotide and nucleoside candidates for
renal autocrine and paracrine ligands within the tubular fluid
of the nephron. This minireview discusses the first princi-
ples of purinergic signaling as they relate to the nephron and
the urinary bladder. The review discusses how the lumen of
a renal tubule presents an ideal purinergic signaling
microenvironment. The review also illustrates how remod-
eled and encapsulated cysts in autosomal dominant poly-
cystic kidney disease (ADPKD) and remodeled pseudocysts
in autosomal recessive PKD (ARPKD) of the renal collect-
ing duct likely create an even more ideal microenvironment
for purinergic signaling. Once trapped in these closed
microenvironments, purinergic signaling becomes chronic
and likely plays a significant epigenetic and detrimental role
in the secondary progression of PKD, once the remodeling
of the renal tissue has begun. In PKD cystic microenviron-
ments, we argue that normal purinergic signaling within the
lumen of the nephron provides detrimental acceleration of
ADPKD once remodeling is complete.
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Abbreviations
PCT proximal convoluted tubule
ATP adenosine 5′ triphosphate
ADP adenosine 5′ diphosphate
UTP uridine 5′ triphosphate
UDP uridine 5′ diphosphate
Ado adenosine
RBF renal blood flow
GFR glomerular filtration rate
ARPKD autosomal recessive polycystic kidney
disease
Purinergic Signalling (2008) 4:109–124
DOI 10.1007/s11302-008-9102-6
M. B. Hovater :D. Olteanu : E. A. Welty : E. M. Schwiebert (*)
Department of Physiology and Biophysics,
University of Alabama at Birmingham,
MCLM 740, 1918 University Blvd.,
Birmingham, AL 35294-0005, USA
e-mail: issytman@uab.edu
E. M. Schwiebert
Department of Cell Biology,
University of Alabama at Birmingham,
MCLM 740, 1918 University Blvd.,
Birmingham, AL 35294-0005, USA
E. M. Schwiebert
Recessive PKD Translational and Research Core Centers,
University of Alabama at Birmingham,
Birmingham, AL, USA
E. M. Schwiebert
Comprehensive Kidney Disease Research Center,
University of Alabama at Birmingham,
Birmingham, AL, USA
ADPKD autosomal dominant polycystic kidney
disease
P2 receptors ATP-sensing P2Y G protein-coupled
receptors and ATP-gated P2X receptor
channels
P1 receptors A1, A2a, A2b, and A3 adenosine-
sensing G protein-coupled receptors
ABC transporters ATP-binding cassette transporters
MOATs multiple organic anion transporters
PGP P-glycoprotein
mdr multidrug resistance transporter
PAH para-amino hippurate
cTAL cortical thick-ascending limb
mTAL medullary thick-ascending limb
TAL thick ascending limb
MD macula densa
JGA juxtaglomerular apparatus
DCT distal convoluted tubule
TG feedback tubuloglomerular feedback
Ca2+ calcium
PLC phospholipase C
PKC protein kinase C
ENaC epithelial Na+ channel
H2O water
IC interstitial cystitis
5′ AMP adenosine 5′ monophosphate
Introduction: sites and modes of adenosine
5′ triphosphate secretion and its regulation
along the nephron
Glomerulus A classical example of an autocrine or para-
crine signaling microenvironment is the renal nephron. A
diagram of the classic nephron is provided in Fig. 1. Within
the glomerular capillaries, red and white blood cells alike
are squeezed through these small capillaries and deformed
in the process. Sprague and coworkers studied deformation-
induced adenosine 5′ triphosphate (ATP) release in eryth-
rocytes for many years, as have others [1–3]. With regard to
mechanically released ATP, ATP and their metabolites are
present in plasma at finite amounts, and the amount of
nucleotides and nucleosides freely filtered at the glomerulus
is likely to be low to negligible. However, deformation of
blood cells may provide more ATP to be filtered than is
appreciated. More likely, however, nucleotides are secreted
under basal conditions and in response to a variety of
mechanical, osmotic, and chemical stimuli by most—if not
all—cells of the glomerulus and its associated vasculature,
as well as the proximal tubule cells rich in mitochondria [4–
6]. Ecto-ATPases and ectoadenosine 5′ diphosphatases
(ADPases) are also present throughout the nephron [7–
12], although their nephron-specific localization has not
been studied in depth. Their action generates metabolites
that are also active at P2 receptors [ADP and uridine 5′
diphosphate (UDP)] [13–15]. Ecto-5′-nucleotidases are also
present at discrete points along the nephron [16–18].
Nucleotidases have been mapped more precisely along the
nephron, and their enzymatic action generates the well-
known active purinergic metabolite adenosine (Ado), which
binds to and activates P1 receptors [19–21].
Proximal tubule Each purinergic ligand (as pictured in
Fig. 1) can appear or be generated within the lumen of a
renal proximal tubule where it becomes trapped within the
lumen of each single nephron. These ligands can signal at
luminal receptors in the proximal tubule or be carried to
downstream nephron segments by the tubular fluid. The
proximal tubule segments may be a rich and additional
source of secreted ATP for multiple reasons. Despite an
isosmotic environment, flow rate is high through this initial
nephron segment due to renal blood flow (RBF) physical
forces that drive a robust glomerular filtration rate (GFR).
These forces dissipate as the tubular fluid traverses the loop
of Henle. Hence, flow and/or shear stress may be robust
stimuli for ATP secretion in the convoluted and straight
tubules. Other ATP-release mechanisms in proximal tubule
have been postulated and are presented below.
Proximal-tubule-based large anion secretion Drug secre-
tion and organic acid secretion also occur in the proximal
tubule [22–25]. The classic example is para-amino hippurate
(PAH), which is often used as a marker for PCT secretion
[4–6]. It is well known that the proximal tubule is enriched
in the expression of ATP-binding cassette (ABC) trans-
porters [22–25]. In particular, the multiple organic anion
transporters (MOATs) are expressed in abundance [22–25].
Their principal function is the secretion of large organic
anions [22–25], of which ATP is a principal one. Upon
chronic administration of a significant dose of one or more
drugs in a human patient with a disease condition, the
multidrug resistance (mdr) transporters [known as P-
glycoprotein (PGP), etc.] will be upregulated and may also
be a robust transporter conduit for ATP and other large
anions [22–25]. This minireview does not revisit the debate
concerning the role of ABC transporters in ATP transport
and release; however, past reviews of this biology are cited
here for interested parties [13–15, 26, 27].
Loop of Henle: focus on the cortical thick-ascending limb
(cTAL) The loop of Henle and its role in nephron intra-
luminal purinergic signaling is less clear. It may act as a
conduit for ATP filtered at the glomerulus and secreted by
the proximal tubule in order to present a set (ATP) to the
macula densa. Higher flows of tubular fluid than normal
could trigger additional ATP secretion along the loop of
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Henle. Importantly, as water accumulates due to the
impermeability of the thick-ascending limb of the loop of
Henle, this tubular fluid becomes hypotonic with respect to
the interstitium and plasma. As a consequence, ATP
secretion is triggered by hypotonic cell swelling, which
can also be thought of as an osmotic and mechanical
stimulus. Therefore, the existence of the free water in the
cTAL at the level of the macula densa or juxtaglomerular
apparatus (JGA), a tubular fluid normally 100 mOsm/kg
H2O or 100 mOsm/l [4–6], begs a question. Is there
routinely a robust stimulus for ATP secretion at this point in
every nephron? If so, a bolus of ATP secretion is likely
routinely released at the level of the cTAL and distal
convoluted tubule (DCT) to affect collecting duct physiol-
ogy. Could proximal tubule (ATP) or that of its metabolite
(adenosine) be sensed at the level of the JGA? Flow, salt,
and osmolality have been postulated as factors sensed by
the specialized cells of the macula densa. However, an
autocoid that is normally secreted at a certain rate and in a
certain amount due to a normal GFR may be hypersecreted
when RBF and GFR are high and hyposecreted when GFR
is low. This postulate is plausible and is still being actively
pursued. It is also important to state that other autocoids
may serve this role in tubuloglomerular feedback.
Macula densa, cTAL, and tubuloglomerular (TG) feedback A
routine bolus of secreted ATP at the level of the macula
densa agrees with the work of several laboratories
examining the role of purinergic signaling in tubuloglo-
merular (TG) feedback between the macula densa and
nearby afferent arterioles of the glomerulus. Significant
roles for both nucleotides (ATP) and nucleosides (Ado)
have been proposed. From our assessment of the literature,
both families of purinergic ligands are likely involved at
multiple levels in TG feedback. The interstitium composed
of mesangial cells and extracellular matrix interconnected
with the patch of specialized macula densa cells of the
cTAL and the afferent arterioles nearby is another ideal
microenvironment for purinergic signaling. These para-
digms have been reviewed and discussed by several
prominent investigators, including, but not limited to,





















































in proximal tubule cell
brush border and apical





*Bolus of ATP secreted in
response to hypotonic "free

























































In diuresis, the hypotonic
"free water" provides a
continual stimulus for 






































Fig. 1 Nucleotide secretion along the nephron: current postulates. Although not pictured as such, the sources of secreted ATP along the nephron
are the renal epithelial cells themselves that line each nephron segment
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[8, 28–40]. Seminal diagrams in their reviews illustrate their
findings [28–39].
Briefly, Peti-Peterdi and coworkers [31, 35], and Inscho
and colleagues have championed a hypothesis that ATP release
occurs upon the macula densa sensing changes in salt load
and/or flow. The authors, together with Okada and coworkers,
showed that a voltage-dependent anion channel (VDAC) or
porin-like maxi anion channel was a likely candidate to
facilitate ATP secretion by the macula densa cell [31, 40].
Secreted ATP then binds to P2X receptor channels (likely
P2X1 according to Inscho and colleagues [30]) on the afferent
arteriole, causing it to vasoconstrict and creating decreased
RBF and GFR. In elegant imaging using two-photon
technology, Peti-Peterdi [40] and Komlosi et al. [31] showed
the macula densa cells swell in response to a hypotonic cTAL
tubular fluid-like perfusate and the corresponding afferent
arteriole constrict in the individually dissected glomerulus and
cTAL-coupled tissue preparation. In elegant subsequent
work, Peti-Peterdi, in his own laboratory [35], found that a
calcium (Ca2+) wave is triggered by increased flow rate of
cTAL perfusate that was propagated from the macula densa to
both extraglomerular mesangial cells and juxtaglomerular
renin granular cells. This flow-induced Ca2+ wave was also
propagated to distant glomerular podocytes. Uncoupling of
gap junctional connexin channels and scavenging of extra-
cellular ATP and ADP by apyrase and hexokinase abolished
the change in Ca2+ at the macula densa and/or the
propagation of the Ca2+ wave. Garvin and coworkers also
argued for prominent roles of cytosolic Ca2+ and nitric oxide
signaling in macula-densa-driven TG feedback [33, 37, 38].
Inscho and coworkers focused on cell Ca2+ and purinergic
signaling [28, 30]. It is clear that extracellular ATP signaling,
Ca2+ signaling, and other signaling pathways may all play
key roles in macula-densa-triggered TG feedback.
Having presented the above, it is also equally clear from
the work of Schnermann and coworkers and others that
ATP’s metabolite, Ado, may also play an equally important
role in TG feedback [32, 36–39]. They and others have
long held the postulate that a local paracrine mediator
within the confines of the JGA plays a key role in TG
feedback. With early work with an arsenal of partially and
more selective P1 Ado receptor antagonists, they focused
on Ado [32, 36–39]. With mouse genetic approaches, they
found that A1 Ado receptors (that signal via phospholipase
C and cell Ca2+ like P2Y G-protein-coupled receptors and
P2X receptor channels) are absolutely required in the TG
feedback mechanism [32, 36–39]. They also believe that
the renin–angiotensin system plays a parallel role in TG
feedback [36–39]. Garvin and coworkers showed in elegant
work that ATP is indeed released by the macula densa in
response to TG feedback signals in the cTAL; however,
their careful work showed that the released ATP generates
the production of adenosine 5′ monophosphate (5′ AMP)
extracellularly in the JGA interstitium, which is used as a
substrate to create Ado [37]. It is their belief that the
metabolite Ado, is the key final mediator of the TG
feedback mechanism [37]. Osswald et al., Vallon and
others share this belief [39]. Having said that, Inscho et
al., using P2X1-receptor-channel-deficient mice (P2X1 is
prominently expressed on vascular smooth muscle), have
shown a similar deficit in TG feedback [30]. Taken
together, we wonder if the kidney has chosen both ATP
and Ado to achieve a fast, vigorous, complete, and—
possibly—redundant TG feedback mechanism to ensure
that this autoregulatory process remains intact. When such
collegial controversy emerges, both camps are likely
correct. For example, P2X1 may mediate the effects on
smooth muscle surrounding afferent arterioles, whereas
Ado (and possibly ATP in parallel) may affect other cell
types in the JGA to achieve full TG feedback. It is quite
likely that more work will continue to emerge in this field.
Collecting duct: diuresis Following the logic above, intra-
luminal purinergic signaling would be robust in diuresis [4–
6]. Vasopressin is not secreted, aquaporin-2 water channels
are not inserted into the luminal membrane, and the
collecting duct is virtually impermeable to water. As such,
hypotonic free water would remain an osmotic or mechan-
ical stimuli for ATP secretion from the macula densa to the
urinary bladder. The ATP would be significant to high. Its
metabolite Ado would also be present in significant
amounts. The higher amounts of extracellular ATP ligand
are consistent with its effects on sodium (Na+) and water
(H2O) transport in renal collecting-duct epithelia and other
ductal epithelia. Purinergic receptors attenuate epithelial
sodium channel (ENaC)-mediated Na+ absorption via
multiple mechanisms [41–46]. In particular, Unwin and
coworkers and Leipziger and colleagues have shown this
elegantly in multiple in vivo, in-vivo-like, and in vitro
model systems from kidney and other tissues [47–50]. In
the most careful study examining a range of doses of Ado,
Ado had a dual effect on ENaC: inhibition at high
micromolar doses and stimulation at low nanomolar doses
[44]. More recent work by Boucher and coworkers tied
ATP and Ado to stimulation of anion secretion and
inhibition of ENaC-mediated Na+ absorption and the
maintenance of airway surface liquid volume bathing
multiciliated airway epithelium [51]. Along the same lines,
Kishore and coworkers have shown elegantly that ATP
attenuated vasopressin- and prostanoid-driven water per-
meability in collecting ducts [52–54]. They have also begun
to address metabolism of ATP into its metabolites and their
possible actions in collecting ducts.
Collecting duct: antidiuresis In antidiuresis, ATP and Ado
would have only a finite amount of local signaling
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capability due to the free-water-driven bolus of secreted
ATP entering the collecting-duct system. As the luminal
tubular fluid osmolality rises due to water reabsorption in
antidiuresis, ATP secretion would actually be attenuated and
suppressed in areas of isoosmolality and hyperosmolality,
respectively. Therefore, autocrine ATP and Ado signals
would not be present, and Na+ and H2O absorption could
proceed vigorously without purinergic tonic inhibition.
Urinary bladder During the process of micturition or
voiding, urine from the collecting-duct system stretches
the urinary bladder as it is filled. Several groups have found
that purinergic signaling underlies much of the physiology
underlying the micturition process [55–83]. It begins with
the urothelium being stretched by the expanding urinary
bladder, causing stretch- or mechanical-dependent ATP
release [55, 62, 63, 66, 68, 71, 76, 77]. There are roles
for both P2Y G-protein-coupled receptor and P2X receptor
channels in the process [59, 61, 62, 64, 65, 67, 70, 72–75,
79–83]. Their relative expression is visited below in a
section of purinergic receptor expression along the nephron
and urinary tract. However, it is P2X receptor channels that
appear to play a more prominent role in the urinary bladder
[59, 61, 62, 64, 65, 67, 70, 72–75, 79–83]. They are
expressed on the urothelium along with P2Y receptors. P2X
receptors are also abundantly expressed on myofibroblasts
and smooth muscle cells that surround the urinary bladder
[59, 61, 62, 64, 65, 67, 70, 72–75, 79–83]. The stretch-
induced ATP signal from the urothelium affects purinergic
nerves of the urinary bladder to trigger action potentials that
signal the need to void [59, 61, 62, 64, 65, 67, 70, 72–75,
79–83]. This physiology has been proven in obstructed-
detrusor-muscle models where purinergic and cholinergic
signaling are upregulated artificially [59, 61, 62, 64, 65, 67,
70, 72–75, 79–83]. Vanilloid- and capsaicin-driven recep-
tors also play a role in these responses [66, 78, 80, 82]. Pain
also emerged during obstruction to voiding, and it is
partially P2X receptor-channel-driven neurotransmission
[83]. P2X3- and P2X3/P2X2-deficient mice have problems
with the micturition response, proving these findings with
mouse genetics [64, 65, 79, 83]. Chai and Sun have shown
that ATP release and signaling process is heightened in
interstitial cystitis (IC) [63, 77]. There are also alterations in
P2 receptor expression in IC [70, 74]. From this work, the
nonselective purinergic receptor antagonist suramin has
been suggested as an early lead therapeutics for IC, a
chronic, painful, and debilitating syndrome [63]. P2X
receptor channels may provide important targets for
therapeutics that help with incontinence, IC and other
related urinary disorders [56, 57, 75, 76, 81]. Perhaps it is
the urinary bladder that is the most ideal paradigm along
the nephron and urinary tract to study the importance of
underlying autocrine and paracrine purinergic signaling.
It is therefore clear that autocrine and paracrine
nucleotide and nucleoside signaling is robust and dynamic
within the tubular lumen along the entire nephron and
within and outside the urinary bladder. In addition to flow,
osmotic, and mechanical stimuli discussed above, chemical
stimuli could stimulate release of ATP along the entire
nephron if a ligand is present that mobilizes cell calcium or
cyclic nucleotides. Many active autocrine, paracrine, or
endocrine ligands affect renal physiology, and any and all
could trigger additional ATP secretion or Ado accumulation
to that already filtered at the glomerulus or triggered by
mechanical or osmotic stimuli. Figure 1 in its many forms
shows the first principles of extracellular purinergic
signaling as they pertain to the nephron and the kidney.
Ecto-ATPases, Ecto-ADPases, and Ecto-5′ nucleotidases
along the nephron: generation of the active metabolite
adenosine
Knowledge of the expression of ecto-ATPases, ecto-
ADPases, and ecto-5′ nucleotidases in kidney is also
accumulating, and it is critical to determine where extra-
cellular nucleotide signals may diminish and extracellular
nucleoside signals may be created [8–12, 16–18, 84, 85].
Less work has been done on ectokinases or secreted kinases
that may phosphorylate adenine nucleosides to re-create
ATP extracellularly. Elegant work on the extracellular
surface of airway epithelia has documented the presence
of these ectokinases. It is important not to rule out that they
may be present along the nephron or in the urinary bladder.
With regard to ecto-ATPases, Zimmerman and coworkers
and Robson and colleagues are the foremost authorities in
the field. Together with the emerging renal purinergic
expert, Kishore, they documented expression of two
prominent ecto-ATPases, nucleoside triphosphate diphos-
phohydrolase (NTPD)ase-1, an ecto-ATPase and ADPase
that generates accumulating 5′ AMP, the precursor to Ado,
and NTPDase-2, which converts ATP to ADP [8–12, 84,
85]. Both enzymes are related to CD39, an ectoapyrase that
metabolizes both ATP and ADP [8–12, 84, 85]. Interest-
ingly, these enzymes are most abundantly expressed in the
renal vasculature and glomeruli [8–12, 84, 85]. The only
principal nephron segment where nucleoside triphosphate
diphosphohydrolase (NTPD)ase-1 was expressed was in the
thin ascending limbs of the loops of Henle. Multiple studies
have also shown that these ecto-NTPases and -NDPases are
also enriched in microvillar membrane fractions of whole
kidney. Additional ecto-NTPases have been cloned by
Zimmerman and others and they are expressed in most if
not all tissues including kidney [8–12, 84, 85].
These findings agree well with the work of a collabo-
rative study by Schrader, Vallon, Zimmerman, and Osswald
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showing these enzymes expressed together with ecto-5′-
nucleotidase in a coordinated way to facilitate Ado
production from secreted ATP so that Ado could be an
active mediator of TG feedback within the JGA [8].
Kaissling and Le Hir studied comprehensively the
expression and function of ecto-5′-nucleotidase in the
kidney [16–18]. Initial work found abundant expression of
5′ nucleotidase on fibroblasts within the interstitium of the
renal cortical labyrinth. Subsequent work with a second-
generation monoclonal antibody revealed that ecto-5′-nucle-
otidase was expressed on the brush border of proximal tubule
segments and the apical membrane and apical cytoplasm of
intercalated cells of all relevant segments of the collecting
duct [16–18]. Interstitial stellate-shaped fibroblasts were
also reactive [16–18]. Fibroblasts surrounding the afferent
and efferent arterioles of the glomerulus were also positive
[16–18]. However, Kaissling and Le Hir found that all parts
of the JGA were negative [16–18]. As such, the glomerular
fibroblasts may convert 5′ AMP to Ado to aid TG feedback.
However, it may be that intermediate metabolites of ATP,
such as 5′ AMP, may have important actions in TG
feedback on P1 receptors that are not yet appreciated. It is
important to note that extracellular 5′ AMP and cyclic AMP
are often abundant in extracellular samples. Receptors for
these purine species have often been postulated; however,
their existence has yet to be proven. We should not rule out
that these purine metabolites or modified purine molecules
may have specific receptors and receptor-mediated effects
on renal physiology.
Nucleotide and nucleoside receptor expression
along the nephron
No review of renal purinergic signaling would be complete
without a summary of the current state of knowledge about
nucleotide and nucleoside receptor expression in the kidney
[86–108]. The study in 2003 by Turner et al. was perhaps
the most comprehensive study of purinergic receptor
expression to date. They assessed expression along the rat
nephron of P2Y G-protein-coupled receptors 1, 2, and 4.
They coupled this with an assessment of the entire P2X
receptor-channel subfamily, subtypes 1–7 [86]. In the
vasculature, P2X1, P2X2, and P2Y1 expression was
prominent. Within the glomerulus, P2Y1 was expressed
on the mesangial cells, whereas P2Y2 was expressed on
podocytes. P2X1 and P2X2 were present in smooth muscle
cells of the glomerular vasculature, in agreement with the
work of Inscho et al. [30] on TG feedback discussed above.
In the proximal tubule, P2Y4 receptors were present only
on the basolateral membrane and were absent from all other
renal structures. Its exclusive expression of the basolateral
surface of proximal tubules evokes a special physiological
role that is yet to be appreciated. In contrast, apical surfaces
of proximal straight tubule or S3 segments stained for P2Y1
and for P2X5. P2X4 and P2X6 were expressed at lower
levels; however, these two coassembling P2X receptor-
channel subtypes were expressed at lower but significant
levels in all nephron segments, especially in proximal
convoluted tubule and DCT. In the thin and thick ascending
limbs of the loop of Henle, P2Y2 receptors were expressed
mostly intracellularly. P2Y2 receptors were also localized
on intercalated cells of medullary but not cortical collecting
ducts (CCDs). P2X5 receptors were expressed in abundance
on principal cells of the medullary collecting ducts, but
P2X5 expression was diminished in the cortex. In these
normal rat nephrons, P2X7 expression was not observed,
save some low-level expression in only some glomeruli.
Studies are presented below that both agree as well as
depart from this seminal work. The authors do point out
that they were unable to evaluate P2Y6, P2Y11, P2Y12, and
P2Y13 in this study due to lack of workable antibodies.
Much of the work performed previous to this study, and
even studies performed subsequent to this study, relied on
pharmacology as well as rank-order potency of a panel of
different nucleotides, nucleosides, and analogs to determine
which P2Y and P2X receptors may be expressed. Without
any companion molecular biology and biochemistry to
support the pharmacology and physiology, pharmacological
studies of P2Y and P2X receptors can be misleading.
Despite the wealth of literature arguing for selective effects
of many purinergic agonists and antagonists, these ligands
are rarely selective and often bind to multiple P2Y and P2X
receptors to agonize or antagonize receptor activity.
Together, these studies do, however, reveal a common
theme shared by most, if not all, cells and tissues. This tenet
is that there are usually one or more subtypes of the P2Y,
P2X, and P1 receptor subfamilies expressed on any given
renal vascular, glomerular, interstitial, or renal cell. One
might not be able to define what subtypes are expressed
precisely in all studies. However, the effects of purinergic
ligands on a physiological endpoint are often quite dramatic
and difficult to ignore.
Evidence for P2Y and P2X receptors in renal vasculature
was found in a pharmacological study assessing nitric oxide
(NO) production by Eltze and Ullrich [87]. There is
abundant evidence for the expression of multiple P2Y and
P2X receptors of vascular endothelium. Along these lines,
Vonend et al. found messenger ribonucleic acid (mRNA)
expression for P2X4–7 and P2Y1, 2, 4, 6, and 11 in
glomerular epithelial cells [97]. Bailey et al. detected
mRNA for P2Y1, 2, 4, and 6 in glomeruli that was
confirmed by functional analysis using inositol phosphate
production as an endpoint [90]. They confirmed P2Y1
receptor expression in the proximal tubule, showing
inhibition of bicarbonate reabsorption [88]. They also
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assessed the expression of basolateral P2Y receptors along
the nephron by applying different agonists to the bath in
isolated nephron segment preparations [89]. Briefly, they
found that ATP mobilized cell calcium in every nephron
segment, with the exception of the TAL, which was
unresponsive. They found evidence for P2Y1, P2Y2, and
P2Y4 G-protein-coupled receptors on the basolateral sur-
face of most nephron segments [89]. Schwiebert and
colleagues assessed the expression of P2X receptor-channel
subtypes, with the exception of P2X6, which could not be
amplified with their degenerate reverse transcriptase poly-
merase chain reaction (RT-PCR) method [101]. In all
normal cell models derived from known nephron segments,
P2X4 and P2X5 were shared in their abundant expression in
multiple nephron segments [101]. P2X6 is likely also
expressed along most nephron segments, based on the
work of Turner et al. from the Unwin laboratory [86]. In
collecting duct-cell models, the expression pattern shifted to
P2X3 and P2X4 as the most abundantly expressed members
[94, 101]. Schwiebert et al. also documented the appear-
ance of P2X7 to a significant degree at the mRNA level in
primary cultures of human polycystic kidney disease (PKD)
cells versus non-PKD human renal epithelial cell primary
cultures as controls [101]. In a collaborative study with
McCoy and Stanton, they showed expression of P2Y1 and
P2Y2 as well as P2X3 and P2X4 in mIMCD-K2 cells [94].
In studies in mouse DCT cells by Quamme and coworkers
and by Wingo and coworkers in mIMCD-3 cells, expres-
sion and function of both P2Y and P2X purinoceptors was
concluded [92, 93]. Taken together, it appears that renal
epithelial cells that line most nephron segments express
both functional P2Y G-protein-coupled receptors and P2X
receptor channels.
Unwin and colleagues are emerging as the foremost
authorities on purinergic receptor expression in normal and
diseased kidneys. This is not surprising given their past
tutelage in the Burnstock group. They have led the field in
determining that P2X7 expression emerges in apoptotic and/
or diseased renal epithelial, interstitial, and glomerular
cells, which is well documented by several groups [86,
96, 98–100]. In particular, emergence of abundant P2X7
expression has been documented in mouse models and in
human cells and tissues within autosomal recessive
(ARPKD) and autosomal dominant (ADPKD) polycystic
kidney disease [96, 98–100]. In diabetic and hypertensive
rats, P2X7 expression emerged and was abundant in
multiple vascular and nonvascular cell types of the
glomerulus [96, 98–100]. It is important to note that
activation of the P2X7 receptor channel also evokes the
appearance of the opening of large pores that allow dyes to
enter cells and that are used to detect apoptotic cells. There
is debate about whether the P2X7-channel pore undergoes a
conformational change or dilation to conduct these dyes
itself or whether it activates a separate membrane protein-
driven pathway via second messengers and mitogen-
activated protein (MAP) kinase and other kinases [109]. It
also remains unclear to the authors whether P2X7 is a
critical player in the beginnings of apoptosis or whether it is
upregulated as a consequence of apoptosis and is therefore
an important marker of programmed cell death.
It is important to mention that there have been a series of
studies using apically applied ligands to study the luminal
effects of purinergic ligands on Na+ and H2O transport and
other endpoints. Based upon this work, these groups have
concluded that P2U or P2Y2 receptors are the main luminal
receptors involved [102–105]. However, based upon the
work above where parallel molecular, biochemical, and
immunocytochemical work was performed with physiolo-
gy, it is not at all clear that P2Y2 is solely involved or
involved at all. This is where care as well as more
comprehensive studies are needed to confirm that P2Y2 is
a chief luminal purinoceptor in kidney.
In renal epithelial cell models such as Madin-Darby
canine kidney (MDCK) cells and A6, purinergic receptor
expression has also been assessed. Here, P2Y receptors
have been the main focus, and work on P2X receptors has
been less addressed. Insel and coworkers found evidence
for P2Y1, P2Y2, and P2Y11 [106]. In MDCK cells, Ostrom
et al. performed some seminal mechanical perturbation
studies showing marked effects on ATP release [110]. Ado
receptor studies have also been performed on these well-
known renal cell lines, mostly with regard to regulation of
ENaC [41–44]. Ado receptors were not identified in these
studies. However, as with P2 receptors, it is shared
knowledge that both A1 and A2 Ado receptors are
expressed on these renal cell models and on most nephron
segments. Vitzthum et al. showed that A1 Ado receptors
and A2a Ado receptors had marked expression in the cortex
that was less prominent in the medulla [107]. A2b Ado
receptor expression was weak throughout renal tissue [107].
A1 receptors were expressed strongly in the thin limbs of
Henle and in the collecting duct system [107]. A2a receptor
expression was strong in glomeruli. A2b expression within
specific segments was prominent in cTAL and in DCT
[107]. A3 receptors were not found in any tissue of the
kidney [107]. Interestingly, in urinary bladder, Apodaca and
coworkers found that all four P1 Ado-sensing G-protein-
coupled receptors (A1, A2a, A2b, and A3) are expressed in
the urothelium, as determined by Western blot [60]. Ado
increased membrane capacitance of both the apical and
basolateral membranes of the urothelium, suggesting that
Ado stimulates exocytosis. A1 receptors were most active
in the capacitance increase, an electrical measure of
membrane area.
Table 1 provides a synopsis of the above literature with
regard to expression of P2Y, P2X, and P1 receptors along
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the nephron. It also illustrates that each cell and segment
within the kidney express at least one P2Y nucleotide-
sensing G-protein-coupled receptor, one nucleotide-gated
P2X receptor channel, and at least one P1 nucleoside-
sensing G-protein-coupled receptor. The implications of
this for health and disease, knowing that ATP and Ado are
likely secreted and produced in the tubular lumen and the
interstitium, are discussed in more detail below.
More ideal purinergic microenvironments in remodeled
polycystic kidney tissue: a normal purinergic signaling
paradigm in an open system becomes detrimental
in a closed system
Again, in first-principle terms, purinergic ligands are most
potent as local mediators or autocoids [111–123]. They can
be potent as paracrine factors; however, diffusion away
from the source as well as degradation limits their potency.
Purinergic agonists in vivo are not efficient as blood-borne
mediators [111–124]. ATP is degraded rapidly in the
general circulation via multiple membrane-bound and
secreted ecto-ATPases [111–124]. With regard to purinergic
signaling, it is now comprehensively appreciated that: (1)
all cells release ATP from small releasable pools that
account for 0.1% or less of the total intracellular ATP
content (up to 10 μM detectable secreted ATP from 5–
10 mM total intracellular ATP) [111–127]; (2) all cells
express one or more subtypes of the ATP-gated P2X
receptor channels, ATP-sensing P2Y G-protein-coupled
receptors, and Ado-sensing P1 G-protein-coupled receptors
[111–136]; and (3) all cells are influenced by purinergic
ligands via these receptors in similar and different ways
[111–136]. Ado is recycled back into cells via nucleoside
transporters to be used for ATP resynthesis [111–136]. It is
generally agreed upon that purinergic ligand activity is
short lived and the ability of ATP or Ado to bind to and
signal via its many cell-surface receptors is most robust in
tissue microenvironments.
Purinergic signaling and ADPKD The normal renal tissue
microenvironments are conducive to autocrine and para-
crine purinergic signaling. However, they remain open
systems where the tubular fluid enters and leaves a nephron
segment and the final urine exits the kidneys and empties
into the urinary bladder. Remodeled kidney tissue that
occurs in cystic disease and PKD can present an even more
ideal purinergic signaling microenvironment. In presenting
ADPKD—a progressive disease of remodeling that does
not present until the early to middle decades of adulthood—
ends of renal tubules, bile ducts, pancreatic ducts, and renal
collecting ducts pinch off at each end, creating a cyst that
has lost contact and communication from the rest of the
nephron. The cyst is then fully encapsulated by a single
monolayer of cystic epithelial cells. Whereas the initial
stages of the disease involve and require remodeling, the
disease progression observed in ADPKD is quite heteroge-
neous. It is likely that epigenetic factors not directly
associated with mutated genes or proteins contribute
substantially in this secondary phase of the disease that
could be termed the progression phase of ADPKD. In an
encapsulated cyst, the microenvironment or system is
closed. The process of ATP release and autocrine ATP
signaling that normally was significant in an open system
such as a renal tubule is now trapped in the closed lumen of
an ADPKD cyst. The newly remodeled and pathophysio-
Table 1 Nucleotide and nucleoside receptor expression along the nephron
ATP-sensing P2Y GPCRs ATP-gated ATP-gated P2XR Channels Ado-sensing P1 GPCRs
Glomerulus P2Y1, P2Y2, P2Y4, P2Y6, P2Y11 P2X4, P2X5, P2X6, P2X7 A2a, A2b
Podocytes P2Y2
Mesangium P2Y1
VSM Cells P2Y1 P2X1, P2X2
PCT P2Y4 P2X4, P2X5, P2X6 A2b
PST P2Y1, P2Y4 P2X4, P2X5, P2X6 A2b
Thin limbs P2Y2 P2X4, P2X6 A1, A2b
mTAL/cTAL P2Y2 P2X4, P2X5, P2X6 A2b
DCT P2X4, P2X6 A2b
CCD P2X3, P2X4, P2X5, P2X6 A1, A2b
OMCD P2Y2 P2X4, P2X6 A1, A2b
IMCD P2Y1, P2Y2 P2X3, P2X4, P2X5, P2X6 A1, A2b
Urinary bladder
Urothelium P2YRs A1, A2a, A2b, A3
Myofibroblasts
Urinary neurons P2X2, P2X3
Bold indicates a prominent signal in molecular, biochemical, or immunohistochemical terms
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logical microenvironment converts acute purinergic signal-
ing into chronic purinergic signaling.
In past work, our laboratory showed that ATP content
was robust in a subset of cyst fluid samples from ADPKD
kidneys [123]. We also showed that ADPKD cell mono-
layers released ATP across the apical membrane as or more
readily than normal kidney-cell monolayers [123, 124].
This work was almost exclusively performed on primary
cultures of human kidney cells grown as polarized cell
monolayers. We also showed that multiple P2X and P2Y
purinergic receptor subtypes were expressed by normal and
ADPKD primary human-cell monolayers and that nucleo-
tide ligands to both types of P2 receptors could increase cell
Ca2+ and stimulate chloride (Cl−) secretion [124]. We did
not examine intraluminal Ado signaling; however, we
speculated that Ado would accumulate and also be
deleterious. Purinergic receptor-driven stimulation of Cl−
secretion by ATP and by Ado has been well documented in
MDCK cells as well as in other renal epithelial cell model
systems from the collecting duct and in many other
epithelial cell and tissue models [137–151]. The cystic
fibrosis (CF) transmembrane conductance regulator (CFTR)
Cl− channel is often expressed in cyst-lining renal epithelial
cells and may contribute to cyst-fluid accumulation and
expansion [137–151]. It may also be detrimental in cyst-
fluid accumulation and expansion [137–151]. Mouse
models of ADPKD have been crossed recently with CF
mice to test this hypothesis with mouse genetics by Calvet,
Wallace and coworkers at the University of Kansas Medical
Center’s Kidney Institute. Indeed, the results show now
with the correct genetic cross that CFTR and cyclic-AMP
(cAMP)-driven Cl− secretion and signaling are detrimental
to cAMP-driven cyst formation and expansion in mice (DP
Wallace, personal communication). This paper confirms
previous physiological studies with powerful mouse trans-
genic technology to show that normal Cl− secretory
processes within the collecting duct can also be detrimental
when the tissue is remodeled and encapsulated.
From this abundant work by others and by us, we argued
that autocrine and paracrine ATP and Ado signaling could
be detrimental to ADPKD cyst growth and expansion [111–
151]. The detrimental pathophysiological effects could be
the continual stimulation of Cl− and fluid secretion into the
encapsulated cysts and/or the chronic mitogenic effects on
the cells that lined the encapsulated cysts. Not only could
this be detrimental to the progression of ADPKD cysts in
the kidney, but it could also play a deleterious role in cysts
observed in extrarenal tissues in ADPKD as well as in
polycystic syndromes in other tissues, such as ovary and
breast [152], where P2Y and P2X receptors are also
expressed. Having said that, autocrine and paracrine
purinergic signaling may play a very different role in
ARPKD where encapsulated cysts rarely form and only
dilation of renal collecting ducts and biliary duct is
observed in the human disease [153–155]. ARPKD and
ADPKD are very different diseases with respect to the type
of tissue remodeling that occurs [153–155]; this is an
important caveat that needs to be voiced.
There was a reemergence of work in purinergic signaling
in renal epithelial cell model systems and in liver cyst
preparations in 2006. Turner et al. used a three-dimensional
collagen gel culture system in which MDCK cells were
seeded into this gel matrix as it forms [122]. The cells
organized into cyst structures and grew and expanded in
diameter and volume over time in vitro within this gel
matrix. Turner et al. showed elegantly and comprehensively
that release of endogenous purinergic ligands into the
microenvironment surrounding and within these MDCK
cell cysts drove their growth and expansion. Use of the ATP
and ADP scavenger apyrase, as well as some nonspecific
antagonists of P2 receptors, inhibited cyst expansion
markedly. Inhibitors of the extracellular signal-regulated
kinases (ERK) slow cyst growth and expansion more
dramatically. Both P2Y and P2X receptors can trigger
ERK activation [156–158], as can growth factor receptors
[159]. It is well known that purinergic receptor systems can
transactivate growth factor receptor systems and cytokine
receptor systems [134,160]. It is well known that purinergic
ligands can act as mitogens in their own right or comitogens
with growth factors. As illustrated [122] and discussed in the
PKD literature above, the interplay between local puriner-
gic signaling and growth factor signaling may be critically
important in the progression of PKD during remodeling and
after cysts have formed. The monocilium of the ductal
epithelium and the protein products of genes mutated in
PKD may have a central galvanizing role in purinergic and
growth factor signaling crosstalk [161–181].
In cystic ductal epithelial cells from the livers of mouse
models of ARPKD and ADPKD [182], Doctor, Gattone,
Fitz, and coworkers studied the regulation of ion transport
in cystic cholangiocytes by purinergic ligands and recep-
tors. Bile duct epithelia (BDE) encapsulating liver cysts are
positioned to govern cyst expansion, much like the renal
cystic epithelial cells lining renal cysts. Once the cyst has
formed, the detrimental purinergic signaling paradigm
likely has shared characteristics from tissue to tissue. These
authors found that there was robust anion secretion and
sodium absorption under basal conditions in these cystic
BDE monolayers grown in primary culture from isolated
liver cysts. It is laborious work to isolate cholangiocytes
from cystic structures. It was not possible to harvest enough
noncystic cholangiocytes from isolated bile duct units for
comparison of unaffected and affected tissue. However, the
authors did show that elevation of cAMP agonists or
extracellular nucleotides induced robust Cl− secretion. They
also showed the presence of a key purinergic receptor, the
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P2X4 receptor channel, on the cystic BDE. Importantly, as
in our ADPKD renal cyst fluid studies, these investigators
also found significant ATP levels in a subset of cyst fluid
samples. They also went a step beyond our former study by
applying cyst fluid to the apical surface of cystic BDE cell
monolayers. For those cyst fluids that stimulated anion
secretion, the ATP and ADP scavenger apyrase, an NTPase/
NDPase, abolished the stimulatory effects of the cyst fluid,
illustrating that the active mediator was indeed, either ATP,
UTP, ADP, or UDP.
Figure 2 illustrates trapped purinergic signaling in
encapsulated ADPKD cysts. It is our hope that the ADPKD
research community applies these findings to collagen gel
studies of primary human ADPKD cell cysts or to kidney
organ culture models where cyst formation can be visual-
ized. In these models, it is also highly likely that
antagonism of local purinergic signaling may slow cyst
progression and that existing as well as novel therapeutics
may be brought to bear on ADPKD pathogenesis.
Purinergic signaling in ARPKD As mentioned briefly
above, ARPKD is a very different disease in its presenta-
tion and in its tissue remodeling. ARPKD presents in utero
and in the neonatal period. Patients who survive the early
neonatal period (a significant number do not because of
respiratory insufficiency due to respiratory hypoplasia)
uniformly develop severe and debilitating hypertension. It
is our view that upregulated Na+ hyperabsorption may also
explain respiratory hypoplasia; however, this postulate will
be difficult to prove [155]. The underlying etiology of this
hypertension may be upregulated Na+ absorption in the
collecting duct, as evidenced by Satlin and coworkers as
well as our laboratory [155]. However, in contrast to
ADPKD, renal tubules and bile ducts dilate and are deemed
as pseudocysts in ARPKD; however, they rarely if ever
pinch off and form fully encapsulated cysts. As such, the
pathophysiological tissue system remains open. Perhaps,
Na+ hyperabsorption prevents full remodeling. Neverthe-
less, purinergic signaling may be robust in areas of the
pseudocysts where there are unstirred layers or areas of
turbulent flow. Purinergic signaling could drive detrimental
Cl− secretion to cause expansion of these pseudocysts.
Since purinergic signaling and its possible detrimental role
is being reexamined in ADPKD, purinergic signaling
should also be examined in ARPKD.
Having said that, laboratories have become obsessed
with the cell biology and physiology of the monocilium in
both forms of PKD [161–181]. In particular, we and others
have investigated the roles of the monocilium, flow, and
























Fig. 2 Purinergic signaling in an encapsulated ADPKD cyst. The
progression of remodeling in ARPKD versus ADPKD is shown in
diagram format. Whereas some longer-lived extracellular ATP and
adenosine (Ado) signaling may occur in dilated ARPKD segments,















































Fig. 3 Postulated detrimental roles of purinergic signaling in an
ARPKD pseudocyst or ADPKD cyst. Although ARPKD pseudocysts
are not fully encapsulated, they may close off periodically due to
limits in space between noncystic and cystic tissue parenchyma,
leading to similar problems that occur in ADPKD encapsulated cysts.
Adenosine stimulation of cyclic AMP and cystic fibrosis transmem-
brane-conductance-regulator (CFTR)-driven salt and water secretion
and ATP stimulation of calcium-driven salt and water secretion are
pictured, and both may proceed in parallel to the detriment of volume
expansion in the cysts
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autocrine ATP signals in renal cell models of the collecting
duct. In particular, cilium-dependent Ca2+ signals have been
in sharp focus. Taken together, it is clear that mechanically
induced Ca2+ signals are partially attenuated when the
cilium is missing and that the cilium-derived Ca2+ signal
derives from both Ca2+ entry from extracellular stores and
Ca2+ release from intracellular stores. For the latter Ca2+
release source, it is postulated that there is a Ca2+ store near
the monocilium and the basal body that may be coupled to
the plasma membrane. It is clear that a flow stimulus or a
physical bending of the monocilium sparks a Ca2+ transient.
If the Ca2+ spark or transient is robust enough, it can trigger
a Ca2+ wave across many cells within a monolayer or
tubule or duct. However, it is also well known that
autocrine and paracrine purinergic signaling can propagate
Ca2+ signals or waves. Satlin and coworkers showed in
isolated perfused CCDs from Tg737orpk mice that the
monocilium was indeed required for a full flow-induced
Ca2+ signal [183]. They did not assess a role for underlying
autocrine purinergic signaling. In contrast, Leipziger and
colleagues assessed pressure-pulse-induced Ca2+ signaling
in nonciliated (immature) and ciliated (mature) MDCK cells
[184]. This laboratory found pressure-pulse-induced Ca2+
signals from both MDCK cell preparations and showed that
purinergic signaling played a direct role in the Ca2+ signal
observed.
Although this pressure pulse is a different mechanical
stimulus than flow, we sought to rectify these partially
opposing results with our preparation of cilium-deficient
versus cilium-competent CCD principal cell monolayers
from the Tg737orpk mouse model of cystic kidney disease.
Indeed, flow-induced Ca2+ signals were significantly more
robust in cilium-competent cell monolayers versus cilium-
deficient cell monolayers. However, infusion of gadolinium
Cl− or apyrase abolished the flow-induced Ca2+ signal in
cilium-competent cell monolayers. We also examined basal
versus stimulated ATP release in both principal cell models.
Basal ATP release across the apical cell membrane was not
different between cilium-deficient and cilium-competent
cell monolayers. Basolateral ATP release was negligible in
both preparations. However, stimulated ATP release by
mechanical perturbation, hypotonic cell swelling, and
cytosolic calcium mobilization was greatly attenuated in
cilium-deficient cell monolayers versus cilium-competent
cell monolayers. An accompanying paper in this issue
shows these results in detail. We hypothesize that both the
monocilium and an autocrine ATP signal are critical for the
monocilium-derived Ca2+ signal. We postulated that a
releasable ATP pool and a Ca2+ store may be dedicated to
the monocilium of a fully differentiated ductal epithelial
cell. When both are missing due to a lost or dysfunctional
cilium, monocilium-derived signaling may be lost, leading
to heightened Na+ absorption via multiple mechanisms as
well as the myriad additional effects on cell proliferation,
remodeling, extracellular matrix deposition, regulation of
cell polarity, and gene regulation.
Figure 3 provides a diagram illustrating the detrimental
epigenetic role that trapped purinergic signaling may play
in the secondary progression of ADPKD after remodeling.
Mitogenic effects of purinergic signaling, as well as
crosstalk with growth factor receptor signaling (also
aberrant in PKD), is also illustrated. With emergence of
new studies seeking to define this hypothesis, it is quite
likely that purinergic receptors may be viable therapeutic
targets to attenuate secondary ADPKD disease progression.
Future directions
Through writing this review, it became more clear to us that
purinergic signaling plays essential roles in normal renal
physiology—from the glomerulus to the urinary bladder.
There is also emerging clarity that trapped purinergic
signaling mediated by both ATP and Ado may, indeed, be
a detrimental epigenetic factor in the acceleration of
progression of ADPKD. More definitive work on puriner-
gic signaling is required in ARPKD to assess any possible
detrimental contribution. We hope this review induces other
laboratories, as well as our own, to continue to define renal
purinergic signaling in health and disease.
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